Tumors harboring TP53 mutations progress more rapidly and are more resistant to anticancer therapy than tumors harboring wild-type p5387, indicating that p53 mutants not only lose their tumor suppressor effects but also acquire new oncogenic activities that promote cancer progression. This evidence concerns the gene TP53 and neoplasm.